Por favor, use este identificador para citar o enlazar este ítem: https://doi.org/10.1038/cdd.2014.202

Título: PARP-2 sustains erythropoiesis in mice by limitingreplicative stress in erythroid progenitors
Fecha de publicación: jul-2015
Editorial: Springer Nature
Cita bibliográfica: Cell Death & Differentiation, 2015, Vol. 22, pp. 1144-1157
ISSN: Print: 1350-9047
Print: 1476-5403
Palabras clave: Molecular biology
Resumen: Erythropoiesis is a tightly regulated process in which multipotential hematopoietic stem cells produce mature red blood cells. Here we show that deletion of poly(ADP-ribose) polymerase-2 (PARP-2) in mice leads to chronic anemia at steady state, despite increased erythropoietin plasma levels, a phenomenon not observed in mice lacking PARP-1. Loss of PARP-2 causes shortened lifespan of erythrocytes and impaired differentiation of erythroid progenitors. In erythroblasts, PARP-2 deficiency triggers replicative stress, as indicated by the presence of micronuclei, the accumulation of γ-H2AX (phospho-histone H2AX) in S-phase cells and constitutive CHK1 and replication protein A phosphorylation. Transcriptome analyses revealed the activation of the p53-dependent DNA-damage response pathways in PARP-2-deficient cells, culminating in the upregulation of cell-cycle and cell death regulators, concomitant with G2/M arrest and apoptosis. Strikingly, while loss of the proapoptotic p53 target gene Puma restored hematocrit levels in the PARP-2-deficient mice, loss of the cell-cycle regulator and CDK inhibitor p21 leads to perinatal death by exacerbating impaired fetal liver erythropoiesis in PARP-2-deficient embryos. Although the anemia displayed by PARP-2-deficient mice is compatible with life, mice die rapidly when exposed to stress-induced enhanced hemolysis. Our results pinpoint an essential role for PARP-2 in erythropoiesis by limiting replicative stress that becomes essential in the absence of p21 and in the context of enhanced hemolysis, highlighting the potential effect that might arise from the design and use of PARP inhibitors that specifically inactivate PARP proteins.
Autor/es principal/es: Farrés, J.
Llacuna, L
Martín Caballero, J
Martínez Cáceres, Carlos Manuel
Lozano, J. J.
Ampurdanés, C.
López Contreras, A. J.
Florensa, L.
Navarro, J.
Ottina, E.
Dantzer, F.
Schreiber, V.
Villunger, A.
Fernández Capetillo, O.
Yélamos, J.
Versión del editor: https://www.nature.com/articles/cdd2014202
URI: http://hdl.handle.net/10201/148654
DOI: https://doi.org/10.1038/cdd.2014.202
Tipo de documento: info:eu-repo/semantics/article
Número páginas / Extensión: 14
Derechos: info:eu-repo/semantics/embargoedAccess
Descripción: © 2015 Macmillan Publishers Limited. This document is the Published version of a Published Work that appeared in final form in Cell Death & Differentiation. To access the final edited and published work see https://doi.org/10.1038/cdd.2014.202
Aparece en las colecciones:Artículos

Ficheros en este ítem:
Fichero Descripción TamañoFormato 
04 2015 PARP2 ERITROPIESIS CELL DEATH AND DIFF.pdf4,99 MBAdobe PDFVista previa
Visualizar/Abrir    Solicitar una copia


Los ítems de Digitum están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.